Open AccessDevelopment of an anti‐BAG3 humanized antibody for treatment of pancreatic cancer
Author(s) -
Basile Anna,
De Marco Margot,
Festa Michelina,
Falco Antonia,
Iorio Vittoria,
Guerriero Luana,
Eletto Daniela,
Rea Domenica,
Arra Claudio,
Lamolinara Alessia,
Ballerini Patrizia,
Damiani Verena,
Rosati Alessandra,
Sala Gianluca,
Turco Maria Caterina,
Marzullo Liberato,
De Laurenzi Vincenzo
Publication year - 2019
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12492
Subject(s) - bag3 , pancreatic cancer , humanized antibody , cancer research , antibody , medicine , pancreatic ductal adenocarcinoma , cancer , immunology , biology , apoptosis , monoclonal antibody , autophagy , biochemistry
We have previously shown that secreted BAG3 is a potential target for the treatment of pancreatic ductal adenocarcinoma and that pancreatic tumor growth and metastatic dissemination can be reduced by treatment with an anti‐BAG3 murine antibody. Here, we used complementarity‐determining region (CDR) grafting to generate a humanized version of the anti‐BAG3 antibody that may be further developed for possible clinical use. We show that the humanized anti‐BAG3 antibody, named BAG3‐H2L4, abrogates BAG3 binding to macrophages and subsequent release of IL‐6. Furthermore, it specifically localizes into tumor tissues and significantly inhibits the growth of Mia PaCa‐2 pancreatic cancer cell xenografts. We propose BAG3‐H2L4 antibody as a potential clinical candidate for BAG3‐targeted therapy in pancreatic cancer.